SMYD3 and hepatocellular carcinoma: The upregulated SMYD3 is found to promote the expression of ZEB1, Snail, and MMP9 to induce EMT via interacting with SMAD2/3, resulting in the sorafenib resistance of hepatocellular carcinoma.217